Divide Runs Deep Over Medicare B Drug Payment Experiment
Executive Summary
A May 17 hearing examining the Obama administration's proposed plan to test alternative payment methods for drugs covered under Medicare Part B highlighted the deep divide that exists not only between Republicans and Democrats, but within the latter party itself. The Centers for Medicare & Medicaid Services, which proposed the experiment, wasn't invited to the hearing.
You may also be interested in...
Medicare Chief: Engage With Us On Payment Experiment
Centers for Medicare & Medicaid Services (CMS) acting administrator Andy Slavitt entered the lion's den on March 9 and faced about 300 hundred drug company executives and other health care stakeholders at a meeting in Washington the day after releasing a controversial proposal to overhaul the way the government pays for outpatient prescription medicines, which had some industry leaders up in arms before it was even officially revealed.
PhRMA Condemns Medicare B Rx Drug Payment Experiment
The Pharmaceutical Researchers and Manufacturers of America (PhRMA) wasted no time in condemning the Obama administration's plans to launch a new experiment testing whether alternative payment designs may lead to reducing Medicare Part B expenditures, while preserving and potentially even enhancing beneficiaries' quality of care.
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.